Coherus Oncology Sets Sights on $33 Billion Market Opportunity
Coherus Oncology has announced a strong start to the year, with the company's Q1 2026 earnings call revealing a clear strategy for growth and expansion. At the helm of this effort is LOQTORZI, a next-generation PD-1 inhibitor that is set to play a crucial role in the company's future success.
LOQTORZI has already shown its potential as a revenue generator in the treatment of nasopharyngeal cancer, and its combination with novel molecules in Coherus' pipeline holds even greater promise. The company is optimistic about the prospects for LOQTORZI to become a revenue multiplier, citing the example of its combination with casdozokitug, which is being explored in liver cancer.
Coherus CEO Denny Lanfear outlined the company's strategy during the earnings call, highlighting the importance of LOQTORZI and the potential for proprietary combinations with pipeline assets. "We are executing a well-integrated financial, commercial, and development strategy that maximizes LOQTORZI's potential across both these dimensions while moving the pipeline forward efficiently," he said.
The company's plans for LOQTORZI include label expansion in various cancer indications, including gastrointestinal, head and neck, and prostate cancer. This will provide a significant boost to Coherus' commercial operations, with Sameer Goregaoker, Chief Commercial Officer, stating that the company is projecting revenues of $15 million per quarter by 2027 and $175 million a year peak share by 2028.
Coherus is also exploring Treg depletion with tagmokitug across cancers and non-proprietary combinations. This involves partnering with other companies to develop treatments that target the immune system's regulatory cells, which can be hijacked by cancer to evade treatment. The company has already entered into a partnership with Johnson & Johnson in prostate cancer, and is exploring further opportunities.
Dr. Theresa LaVallee, Chief Scientific Officer, provided context for these developments during the earnings call, noting that Treg depletion presents both therapeutic promise and challenges. "You need to have the right molecule and the right target," she said, emphasizing the importance of selectivity, affinity, pharmacology, and other factors in successful Treg depletion treatments.
Despite some market participants pausing or stopping their Treg depletion programs, Coherus remains committed to advancing this area of research. With a strong pipeline and a clear strategy for growth, the company is well-positioned to capitalize on emerging trends in cancer treatment.
